BioPharmaDispatch, also BPDInsights.ai, is publishing an edited version of the information provided to the unidentified participants in the second stage of the Delphi study on the definitions of 'high unmet medical need' and 'high added therapeutic value'. At least this way, those excluded can see its direction.
Now you can see the next step in the process most are officially excluded from
June 1, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 19 June
June 19, 2026 - - Podcast -
Gilead rushes remdesivir to Uganda to support Ebola response
June 19, 2026 - - Latest News -
Infectious diseases across the lifespan are a hidden burden beyond the acute episode
June 19, 2026 - - Latest News -
Sanofi volunteers confront homelessness at Vinnies CEO Sleepout
June 19, 2026 - - Latest News -
Rhapsido approved in Australia as first oral targeted option for chronic spontaneous urticaria
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News

